Can low serum sodium with fluid retention indicate dilutional (hypervolemic) hyponatremia?

Low serum sodium accompanied by signs of fluid retention is a classic indicator of hypervolemic dilutional hyponatremia. This condition occurs when the kidneys retain water out of proportion to sodium, leading to a diluted concentration of sodium in the bloodstream.

Clinical evidence

The diagnosis of hypervolemic hyponatremia is based on the biochemical finding of serum sodium <135 mmol/L paired with clinical evidence of expanded extracellular fluid (ECF).

• Physical markers: The presence of peripheral edema, ascites, elevated jugular venous pressure, or pulmonary crackles are definitive signs of a hypervolemic state.
• Effective Arterial Blood Volume (EABV): In conditions like heart failure and cirrhosis, there is a paradoxical "underfilling" of the arterial circulation despite an overall expansion of total body water and sodium. This low EABV is sensed by baroreceptors, triggering compensatory mechanisms that exacerbate fluid retention.
• Laboratory findings: Diagnosis is further confirmed by low effective serum osmolality (<275–280 mOsm/kg). In heart failure and cirrhosis, urine sodium is typically low (<20–30 mmol/L) as the kidneys attempt to conserve sodium despite the ECF expansion.

Mechanistic explanations

The primary driver of dilutional hyponatremia is the non-osmotic release of arginine vasopressin (AVP), also known as antidiuretic hormone (ADH).

• Hormonal signaling: Despite low plasma osmolality (which should normally suppress ADH), non-osmotic triggers—such as low EABV—stimulate the hypothalamus to release ADH.
• Molecular pathway: ADH binds to V2 receptors on the basolateral membrane of renal collecting duct cells. This activates a cAMP-mediated pathway that causes the trafficking and apical membrane insertion of Aquaporin-2 (AQP2) water channels.
• Water reabsorption: These AQP2 channels allow for the massive reabsorption of electrolyte-free water back into the blood, rather than allowing its excretion as dilute urine. This process results in a relative excess of free water compared to total body sodium.

Safety and clinical implications

Recognizing the hypervolemic nature of this hyponatremia is vital for safe treatment.

• Volume management: Unlike hypovolemic hyponatremia, which requires saline administration, hypervolemic states are managed with fluid restriction and diuretics.
• Aquaresis: V2-receptor antagonists (vaptans) can specifically block the ADH pathway, promoting "aquaresis" (the excretion of electrolyte-free water) to correct the water-to-sodium imbalance without significantly depleting sodium levels.

Bottom line

Low serum sodium with signs of fluid retention signifies hypervolemic dilutional hyponatremia, where non-osmotic vasopressin release causes the kidneys to retain free water in excess of sodium. This is a common complication in heart failure and cirrhosis, requiring treatment focused on water restriction rather than sodium replacement.